Xiao Ding

Chinese Academy of Sciences

H指数:14

被引数:816

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Design, synthesis, and anti-SARS-CoV-2 activity of vilazodone derivatives as METTL3 inhibitors

vilazodone衍生物的设计、合成及其作为METTL3抑制剂的抗SARS-CoV-2活性

European Journal of Medicinal Chemistry

IF5.9

2026-07-010

PRE

An Internal Sulfur-Lone Pair Interaction Enabled the Discovery of Potent and Sub-Family Selective PKMYT1 Inhibitors

内部硫-孤对电子相互作用促成了高效且亚家族选择性的PKMYT1抑制剂的发现

ChemMedChem

IF3.4

2026-03-270

PRE

Recent advance in macrocyclic CDK inhibitors

近年来大环CDK抑制剂的最新进展

FUTURE MEDICINAL CHEMISTRY

IF3.4

2025-12-010

PRE

Design, Synthesis and Biological Evaluation of Novel, Potent, Selective and Orally Available DGKα Inhibitors for the Treatment of Tumors

新型、高效、选择性且口服可用的DGKα抑制剂的设计、合成及生物评价，用于肿瘤治疗

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2025-12-010

PRE

Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation

人工智能赋能的双功能PKMYT1靶向PROTAC的发现

Nature Communications

IF15.7

2025-11-280

OAAI

Discovery and Biological Evaluation of Novel, Potent, and Orally Available CBLB Inhibitors

新型、高效且口服可用的CBLB抑制剂的发现与生物活性评价

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2025-11-010

PRE

Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor

理性设计与鉴定ISM7594作为组织泛用的FGFR2/3抑制剂

Journal of Medicinal Chemistry

IF6.8

2025-06-250

PRE

Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design; Scaffold Hopping; and Biological Evaluation

基于结构的药物设计、骨架跳跃和生物评价鉴定新型泛KRAS抑制剂

ACS Medicinal Chemistry Letters

IF4

2025-06-050

PRE

Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity

发现具有强效、高度选择性及口服生物利用度的MTA协同PRMT5抑制剂，并展现出强大的体内抗肿瘤活性

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2025-01-090

PRE

Discovery of pyrrolopyrimidinone derivatives as potent PKMYT1 inhibitors for the treatment of cancer

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2025-01-010

PRE

Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2024-12-010

PRE

Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-11-250

PRE

Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-11-090

PRE

Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2024-10-301

PRE

Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2024-05-013

PRE

Discovery of 3-hydroxymethyl-azetidine derivatives as potent polymerase theta inhibitors

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2024-04-016

PRE

Discovery and preclinical characterization of ISM8001, a covalent and selective FGFR2/FGFR3 dual inhibitor with strong monotherapy anti-tumor activity against advanced solid tumors

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-12-266

PRE

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-04-0712

PRE

AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor

Chemical Science

IF7.4

2023-01-01108

OAAI

Xiao Ding

个人简介

教育背景

工作经历

荣誉奖项

研究方向